RIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense.

TitleRIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense.
Publication TypeJournal Article
Year of Publication2017
AuthorsPeterson LW, Philip NH, DeLaney A, Wynosky-Dolfi MA, Asklof K, Gray F, Choa R, Bjanes E, Buza EL, Hu B, Dillon CP, Green DR, Berger SB, Gough PJ, Bertin J, Brodsky IE
JournalJ Exp Med
Volume214
Issue11
Pagination3171-3182
Date Published2017 Nov 06
ISSN1540-9538
KeywordsAnimals, Apoptosis, Cytokines, Disease Resistance, Host-Pathogen Interactions, Immunity, Innate, Macrophages, MAP Kinase Signaling System, Mice, Inbred C57BL, Mice, Knockout, Models, Immunological, NF-kappa B, Receptor-Interacting Protein Serine-Threonine Kinases, Signal Transduction, Survival Analysis, Yersinia pseudotuberculosis, Yersinia pseudotuberculosis Infections
Abstract

Many pathogens deliver virulence factors or effectors into host cells in order to evade host defenses and establish infection. Although such effector proteins disrupt critical cellular signaling pathways, they also trigger specific antipathogen responses, a process termed "effector-triggered immunity." The Gram-negative bacterial pathogen inactivates critical proteins of the NF-κB and MAPK signaling cascade, thereby blocking inflammatory cytokine production but also inducing apoptosis. -induced apoptosis requires the kinase activity of receptor-interacting protein kinase 1 (RIPK1), a key regulator of cell death, NF-κB, and MAPK signaling. Through the targeted disruption of RIPK1 kinase activity, which selectively disrupts RIPK1-dependent cell death, we now reveal that -induced apoptosis is critical for host survival, containment of bacteria in granulomas, and control of bacterial burdens in vivo. We demonstrate that this apoptotic response provides a cell-extrinsic signal that promotes optimal innate immune cytokine production and antibacterial defense, demonstrating a novel role for RIPK1 kinase-induced apoptosis in mediating effector-triggered immunity to circumvent pathogen inhibition of immune signaling.

DOI10.1084/jem.20170347
Alternate JournalJ. Exp. Med.
PubMed ID28855241
PubMed Central IDPMC5679171
Grant ListP30 DK050306 / DK / NIDDK NIH HHS / United States
R01 AI128530 / AI / NIAID NIH HHS / United States
R37 AI044828 / AI / NIAID NIH HHS / United States
T32 GM007170 / GM / NIGMS NIH HHS / United States

Person Type: